Nanette H Bishopric MD
Cardiovascular Disease Genetics, Cardiac Critical Care, Clinical Pharmacology
Professor, Oncology, Georgetown University School of Medicine Cardiology Faculty, Medstar Georgetown University Hospital, Professor Emerita, University of Miami School of Medicine
Join to View Full Profile
Georgetown Lombardi Comprehensive Cancer Center,3970 Reservoir Rd NW, RB E512Washington, DC 20057
Dr. Bishopric is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Cardiovascular Disease, 1985 - 1990- University of California (San Francisco)Fellowship, Cardiovascular Disease, 1983 - 1985
University of FloridaResidency, Internal Medicine, 1981 - 1983
Duke University HospitalFellowship, Hematology and Medical Oncology, 1980 - 1981- University of FloridaInternship, Internal Medicine, 1979 - 1980
Duke University School of MedicineClass of 1978
Certifications & Licensure
CA State Medical License 1983 - Present
DC State Medical License 2018 - 2026
FL State Medical License 1980 - 2023
NC State Medical License 1981 - 1986
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Member Association of University Cardiologists, 2013
- Member American Clinical and Climatological Association, 2011
- Distinguished Scientist Award American College of Cardiology, 2010
- Join now to see all
Publications & Presentations
PubMed
- Pharmacokinetics and pharmacogenomics of ribociclib in black patients with metastatic breast cancer the LEANORA study.Ilana Schlam, D Max Smith, Cody Peer, Tristan Sissung, Keith T Schmidt
NPJ Breast Cancer. 2024-09-30 - 68 citationsTrastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapiesNaomi Dempsey, Amanda Rosenthal, Nitika Dabas, Yana Kropotova, Marc E. Lippman
Breast Cancer Research and Treatment. 2021-06-11 - 2 citationsAdverse Cardiovascular Events in Cancer Trials: Missing in Action?Nanette H. Bishopric, Marc E. Lippman
Journal of the American College of Cardiology. 2020-02-18
Press Mentions
Glaring Gap in CV Event Reporting in Pivotal Cancer TrialsFebruary 12th, 2020
Heart Data Often MIA from Cancer TrialsFebruary 11th, 2020
Trials of New Cancer Drugs Failing to Address Potential CV RisksFebruary 10th, 2020- Join now to see all
Grant Support
- Transcription Programming In Cardiac GrowthNational Heart, Lung, And Blood Institute2003–2011
- Beta-Adrenergic Regulation Of A Myocardial Actin GeneNational Heart, Lung, And Blood Institute1996–1997
- Beta-Adrenergic Regulation Of A Myocardial Actin GeneNational Heart, Lung, And Blood Institute1994–1996
- Evidence For PDGF Activity In A Model Of Vascular InjuryNational Heart, Lung, And Blood Institute1985–1986
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
